Document is current
Any future updates will be listed below
-
Authors
Pilcher, William C. https://orcid.org/0000-0002-8544-4967
Yao, Lijun
Gonzalez-Kozlova, Edgar https://orcid.org/0000-0002-6948-0626
Pita-Juarez, Yered
Karagkouni, Dimitra
Acharya, Chaitanya R.
Michaud, Marina E.
Hamilton, Mark https://orcid.org/0000-0003-2931-1307
Nanda, Shivani https://orcid.org/0000-0001-6358-2392
Song, Yizhe https://orcid.org/0000-0001-8760-6432
Sato, Kazuhito
Wang, Julia T. https://orcid.org/0000-0002-2233-8841
Satpathy, Sarthak
Ma, Yuling
Schulman, Jessica
D’Souza, Darwin
Jayasinghe, Reyka G.
Ohlstrom, Denis https://orcid.org/0000-0003-1920-6319
Ferguson, Katherine E.
Cheloni, Giulia
Bakhtiari, Mojtaba
Pabustan, Nick
Nie, Kai
Foltz, Jennifer A.
Saldarriaga, Isabella
Alaaeldin, Rania
Lepisto, Eva
Chen, Rachel
Fiala, Mark A. https://orcid.org/0000-0002-0208-5023
Thomas, Beena E.
Cook, April
Santos, Junia Vieira Dos
I-ling, Chiang
Figueiredo, Igor
Fortier, Julie
Slade, Michael https://orcid.org/0000-0001-8092-6644
Oh, Stephen T.
Rettig, Michael P. https://orcid.org/0000-0002-1091-0564
Anderson, Emilie
Li, Ying
Dasari, Surendra
Strausbauch, Michael A.
Simon, Vernadette A.
,
Chiang, I-ling
Kalavros, Nikolaos
Rogers, Jennifer
Dawson, Travis
Lee, Brian H.
Kelly, Geoffrey
Walker, Laura
Fernandez, Nicolas F.
Leech, John
Morgenroth-Rebin, Jarod
Angeliadis, Krista
Wyczalkowski, Matthew A.
Cao, Song
Ibrahim, Omar
Lin, Roderick
Fehniger, Todd A.
Houston, Andrew
Radkevich, Emir
Rahman, Adeeb H.
Chen, Zhihong https://orcid.org/0000-0001-7403-7015
Lagana, Alessandro
DiPersio, John F. https://orcid.org/0000-0002-0429-3133
Rosenblatt, Jacalyn
Kim-Schulze, Seunghee https://orcid.org/0000-0003-0192-4400
Lonial, Sagar
Kumar, Shaji https://orcid.org/0000-0001-5392-9284
Bhasin, Swati S.
Kourelis, Taxiarchis
Dhodapkar, Madhav V. https://orcid.org/0000-0002-8249-5988
Vij, Ravi
Avigan, David https://orcid.org/0000-0003-4624-6017
Cho, Hearn J.
Mulligan, George https://orcid.org/0009-0009-5084-9604
Ding, Li https://orcid.org/0000-0003-1517-2975
Gnjatic, Sacha https://orcid.org/0000-0001-5643-9520
Vlachos, Ioannis S. https://orcid.org/0000-0002-8849-808X
Bhasin, Manoj https://orcid.org/0000-0001-5172-420X
-
Funding
Funding for this research was provided by:
Multiple Myeloma Research Foundation Fellowship Program
Multiple Myeloma Research Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R50CA211466)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5K12CA090628)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24CA211006)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U2CCA233303)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (PJ000021702)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24CA224319)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01DK124165)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA196521)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA258776)
Paula C. and Rodger O. Riner Blood Cancer Research Fund
Paula C. and Rodger O. Riney Blood Cancer Research Fund
Multiple Myeloma Research Foundation, Myeloma Solutions Funds
- License Information
-
More Information
Article History
Received: 17 March 2025
Accepted: 10 October 2025
First Online: 9 January 2026
Competing interests
: S.G. reports other research funding from Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, Regeneron and Takeda and consulting from Taiho Pharmaceuticals, not related to this study. J.F.D. is on the consulting or advisory committee for Rivervest, Bioline, Amphivena, Bluebird, Celegene, Incyte, NeoImuneTech and Macrogenics and has ownership investment in Magenta and Wugen. J.R. declares consulting with Attivare, Parexel, Clario/Bioclinica, Imaging Endpoint and Wolters Kluwer Health, serves on a data and safety monitoring board with Karyopharm and has received grants and nonfinancial support from Celgene, BMS and Sanofi. J.R. also has a patent (PCT/US2021059199) pending. S.K. declares research funding for clinical trials to the institution from Abbvie, Amgen, Allogene, BMS, Carsgen, GSK, Janssen, Roche-Genentech, Takeda and Regeneron, as well as consulting or advisory board participation (with no personal payments) for Abbvie, BMS, Janssen, Roche-Genentech, Takeda, Pfizer, Loxo Oncology, K36, Sanofi, ArcellX and Beigene. T.K. declares research funding from Novartis and Pfizer, as well as advisory board participation for BMS. D.A. declares grants from MMRF, CTN (National Heart, Lung and Blood Institute), Celgene, Pharmacyclics and Kite Pharma, as well as other support from Juno, Partners TX, Karyopharm, BMS, Aviv MedTech, Takeda, Legend Bio Tech, Chugai, Caribou Biosciences, Janssen, Parexel, Sanofi and Kowa. D.A. also has a patent (PCT/US2021/059199) pending. I.S.V. reports grants from NCI, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, Harvard Stem Cell Institute and consulting for Mosaic, AlphaSights, NextRNA and Guidepoint Global outside of the submitted work. J.A.F. is a consultant for Cancer Prevention and Research Institute of Texas and Wugen on work unrelated to the manuscript. Unrelated to this work, J.A.F. has a monoclonal antibody licensed to EMD Millipore and is an inventor on patent or patent applications (WO 2019/152387 and US 63/018,108) licensed to Kiadis and held or submitted by Nationwide Children’s Hospital on transforming growth factor-β-resistant, expanded NK cells. The other authors declare no competing interests.
